FIELD: medicine.
SUBSTANCE: group of inventions relates to pharmacy and therapeutic alimentation. Disclosed is use of a composition containing beta-casein to reduce the risk of developing hyperglycemia caused by consumption of beta-casein A1 in an animal, wherein said beta-casein in composition contains at least 75 % by weight of beta-casein A2. Disclosed are a composition of the corresponding composition and purpose and a method for reducing the risk of developing hyperglycemia caused by consumption of beta-casein A1.
EFFECT: technical result consists in reduction of blood glucose level by reducing activity of dipeptidylpeptidase IV (DPP-4) in tissue of small intestine.
24 cl, 7 dwg, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BETA-CASEIN A2 AND BLOOD GLUCOSE LEVEL | 2014 |
|
RU2802806C1 |
| BETA-CASEIN A2 AND REDUCING OR PREVENTING SYMPTOMS OF LACTOSE INTOLERANCE | 2014 |
|
RU2671562C2 |
| A2 BETA-CASEIN AND REDUCTION OR PREVENTION OF SYMPTOMS OF LACTOSE INTOLERANCE | 2014 |
|
RU2791693C2 |
| BETA-CASEIN A2 AND PREVENTION OF INTESTINAL INFLAMMATION | 2014 |
|
RU2784851C2 |
| BETA-CASEIN A2 AND PREVENTION OF INFLAMMATION OF INTESTINE | 2014 |
|
RU2669553C2 |
| BETA-CASEINS AND INTESTINAL MICROBIOTA | 2016 |
|
RU2769989C2 |
| BETA-CASEIN AND COGNITIVE FUNCTION | 2017 |
|
RU2766194C2 |
| BETA-CASEIN A2 AND ANTIOXIDANT CAPACITY | 2016 |
|
RU2751945C2 |
| APPLICATION OF LACTOPROTEIN MICELLES FOR BABIES WITH RISK OF OBESITY OR DIABETES | 2012 |
|
RU2616525C2 |
| COMBINATION FOR REGENERATIVE THERAPY OF TYPE 1 DIABETES MELLITUS | 2018 |
|
RU2694527C1 |
